Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Chokri Ben Lamine: Clinical Dosing and Special Populations Guide for Apixaban
AI Generated
Apr 12, 2026, 12:56

Chokri Ben Lamine: Clinical Dosing and Special Populations Guide for Apixaban

Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:

“Apixaban Pearls (Indications, Dosing plus, and Special Populations)

Mechanism

  • Leads to Direct Factor Xa inhibitor leads to decrease thrombin generation

Indications 

  • VTE treatment (DVT/PE)
  • Extended VTE prophylaxis
  • Stroke prevention in AF (NVAF)
  • Post-op prophylaxis (hip/knee)

Dosing (Adults)

Acute VTE

  • 10 mg twice daily for 7 days
  • Then 5 mg twice daily

Extended VTE

  • 2.5 mg twice daily after at least 6 months of treatment

AF stroke prevention

  • 5 mg twice daily

Dose reduction AF

  • 2.5 mg twice daily if ≥2 of the following are present:
  1. Age ≥80 years
  2. Body weight ≤60 kg
  3. Serum creatinine ≥133 µmol/L (≈1.5 mg/dL)

Post-operative prophylaxis

  • Hip replacement: 2.5 mg twice daily for 35 days
  • Knee replacement: 2.5 mg twice daily for 12 days

Special Populations 

Renal impairment

  • Creatinine clearance ≥30 mL/min: standard dosing
  • Creatinine clearance 15–29 mL/min: use with caution (dose reduction in atrial fibrillation)
  • Creatinine clearance <15 mL/min or dialysis: limited evidence; avoid use (prefer warfarin)

Hepatic disease

  • Mild (Child–Pugh A): use without dose adjustment
  • Moderate (Child–Pugh B): use with caution
  • Severe (Child–Pugh C): not recommended / contraindicated

Cancer-associated VTE

  •  Preferred option: DOAC in many patients (vs LMWH, depending on bleeding risk and cancer type)
  • Avoid: if active gastrointestinal or genitourinary lesions due to increased bleeding risk

Obesity

  • BMI >40 kg/m² or weight >120 kg: use with caution
  • Consider drug level monitoring (anti–Xa activity) or alternative anticoagulation (LMWH or warfarin)

Elderly

  • Increased bleeding risk
  • Assess carefully for dose reduction criteria and comorbidities

Pregnancy

  • Not recommended
  • Use low-molecular-weight heparin (LMWH)

Breastfeeding

  • Not recommended (insufficient safety data)

Antiphospholipid syndrome (APS)

  • Not recommended, particularly in triple-positive APS
  • Prefer warfarin

Drug interactions

  • Strong CYP3A4/P-gp inhibitors (e.g., azoles, clarithromycin): increased bleeding risk
  • Strong inducers (e.g., rifampin, carbamazepine): reduced efficacy

Bleeding management

  • Specific reversal agent: andexanet alfa (if available)
  • If unavailable: prothrombin complex concentrate (PCC)

Key pearl

  • Apixaban has one of the safest bleeding profiles among direct oral anticoagulants in many hematology patients.”

Find more posts featuring Chokri Ben Lamine on Hemostasis Today.

AF Antiphospholipid Syndrome Apixaban Chokri Ben Lamine Health Hematology Hemostasis Hemostasis News Hemostasis Today LMWH Medicine VTE
NewsFeed